InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,216.29
(
0.04%
)
US TECH 100
17,680.00
(
0.22%
)
Dow Jones
39,469.42
(
0.21%
)
Brent Oil
83.77
(
-0.22%
)
Bitcoin
61,205.91
(
-2.91%
)
Post# of 251781
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119608
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: marthambles post# 215847

Friday, 12/08/2017 7:53:47 PM

Friday, December 08, 2017 7:53:47 PM

Post# of 251781
Re: RVNC trial in plantar fasciitis

regarding the PF trial… The primary and secondary endpoints relate to efficacy, but not to duration.

When botulinum toxin is used for plantar fasciitis, the goal is to alleviate the problem with a single treatment; when this goal is achieved (and there is no retreatment), the “duration of effect” is indefinite rather than a well-defined value. Hence, it would be counter-intuitive for duration of effect to be a secondary endpoint in the PF trial.

Do we anticipate anything coming out of this trial comparing [RT002] efficacy to Botox?

I’m not sure what you’re asking. There is no Botox-comparator arm in the PF trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up